Symposium:
130. Hepatitis C and the Infectious Diseases Community
Friday, October 4, 2013: 2:00 PM-3:30 PM
Room: The Moscone Center: 134 (Hall E)
Co-organized with the IDSA Hepatitis CTaskforce

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • identify and appraise emerging treatments for hepatitis C (HCV) infection including novel direct acting antiviral therapies
  • describe novel HCV treatments for the treatment of patients with chronic HCV infection
  • summarize and recommend strategies for monitoring and managing  HCV-infected patient during treatment with novel HCV regimens

Target Audience: vaccinologists, scientists, researchers, public health practitioners, pharmacists, nurses, members-in-training, investigators, infectious diseases physicians, HIV specialists, HIV clinicians, fellows, clinicians, academicians

Tracks: Investigative ID, HIV-STD-TB, Epidemiology and Infection Control, Adult ID

Interactive Moderators:  Eliot W. Godofsky, MD, Bach and Godofsky and Mark Sulkowski, MD, John Hopkins University School of Medicine

Presentations:

2:00 PM
Interactive Panelist
Marion G. Peters, MD, FRACP

2:20 PM
HCV Treatment: State of the ART
Susanna Naggie, MD

2:50 PM
Interactive Panelist
Arthur Kim, MD, FIDSA

3:10 PM
Interactive Panelist
Camilla Graham, MD, MPH

3:30 PM
Interactive Panelist
Douglas Dieterich, MD

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-070-L01-P

Disclosures:

E. W. Godofsky, AbbVie: Investigator and Scientific Advisor, Consulting fee and Research support
Merck: Investigator, Research support
Boeringer-Ingelheim: Investigator, Research support
Vertex Pharmaceutical: Investigator, Scientific Advisor and Speaker's Bureau, Consulting fee, Research grant and Speaker honorarium
Gilead Pharmaceutical: Investigator, Research support
Novartis: Investigator, Research support
Genentech: Scientific Advisor, Consulting fee
Anadys Pharmaceutical: Investigator, Research support
Idenix Pharmaceutical: Investigator, Research support
Janssen Pharmaceutical: Investigator, Research support

M. Sulkowski, AbbVie: Investigator and Scientific Advisor, Consulting fee and Research grant
BIPI: Investigator, Research Contractor and Scientific Advisor, Consulting fee and Research grant
BMS: Investigator and Scientific Advisor, Consulting fee and Research grant
Gilead : Investigator and Scientific Advisor, Consulting fee and Research grant
Janssen: Consultant, Investigator and Scientific Advisor, Consulting fee and Research grant
Merck : Investigator and Scientific Advisor, Research grant
Pfizer: Steering Committe, Consulting fee
Vertex: Investigator and Scientific Advisor, Consulting fee and Research grant

A. Kim, Gilead Sciences: Scientific Advisor, Consulting fee
Vertex Pharmaceuticals: Scientific Advisor, Consulting fee
Abbvie Pharmaceuticals: Scientific Advisor, Consulting fee
Bristol-Myers Squibb: Investigator, Research grant

C. Graham, Vertex Pharmaceuticals, Inc. : Employee and I left Vertex 9/28/12 and have no financial relationship now, Equity and Salary

D. Dieterich, B.,., Gilead, BMS, Vertex, Genentech: Board Member, Consultant, Investigator and Speaker's Bureau, Consulting fee and Speaker honorarium

S. Naggie, Gilead Sciences: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.